Why we started
Alzheimer’s disease and related cognitive decline affect millions of families, yet accessible early-screening tools remain limited. Conventional pathways often depend on clinic visits, venous draws, or expensive imaging—creating barriers for rural communities, people with limited mobility, and anyone who needs repeated monitoring.
VascuSense extends years of work in microfluidics, biomaterials, and translational R&D toward a single integrated goal: lower-friction, decentralized blood-based screening aligned with the science of plasma proteomics and machine learning for MCI and Alzheimer’s disease.
